Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 111,89 € (+9,72 %). La mediana es de 116,52 € (+14,26 %).
| Comprar |
23 |
| Mantener |
4 |
| Vender |
0 |
Noticias Ir al feed de noticias
Kymera Therapeutics completes KT-621 enrollment early; top-line data due by end of 2026
Kymera Therapeutics said it finished enrollment in the Phase 2b KT-621 atopic dermatitis trial about six months ahead of schedule, with top-line data expected by the end of 2026 and potential Phase 3 initiation around mid-2027. The KT-621 asthma Phase 2b study is enrolling with results expected in late 2027 and an open-label extension available for completers. Kymera expects Phase 1 data for oral IRF5 degrader KT-579 in Q4 2026 and plans a lupus proof-of-concept study thereafter. The company reported $65 million of Q2 collaboration revenue and held about $1.5 billion in cash and investments, providing a runway into 2029. » Más en finance.yahoo.com
Kymera Therapeutics to release results for quarter ended June 30, 2026, on August 5
Kymera Therapeutics will publish results for the quarter ended June 30, 2026, on 05.08.2026; analyst consensus expects a loss per share of $0.713 (prior year: $0.950). Estimated revenues average $32.8 million, well above last year’s $11.5 million (+185.5%). For the fiscal year analysts forecast a mean EPS loss of $3.465 and revenues of about $85.4 million (prior year: $39.2 million). » Más en finanzen.net
Kymera Therapeutics appoints Terence Rooney as chief medical officer
Kymera Therapeutics has appointed Dr. Terence Rooney as chief medical officer. Rooney will lead the global clinical development strategy and advance the portfolio of oral immunology programs. He succeeds Dr. Jared Gollob, who is retiring after eight years and will remain as an advisor through the end of the year. Rooney joins from Johnson & Johnson and brings extensive leadership experience from J&J, Eli Lilly and Roche. » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | jun 2026 | |
|---|---|---|
| Ingresos | 56,95 M | 484,95 % |
| Beneficio bruto | 56,95 M | 614,75 % |
| Beneficio neto | -53,63 M | 17,49 % |
| EBITDA | -53,56 M | 15,17 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 8913,65 M € |
Número de acciones | 82,26 M |
Máximo/mínimo de 52 semanas | 112,25 € - 34,39 € |
| Dividendos | No |
Beta | 1,95 |
Ratio P/E | -38,63 |
Ratio PEG | -6,95 |
Ratio P/B | 8,17 |
Ratio P/S | 98,37 |
Perfil de la empresa
Kymera Therapeutics, Inc. ist ein biopharmazeutisches Unternehmen, das sich auf die Entdeckung und Entwicklung neuartiger niedermolekularer Therapeutika konzentriert, die selektiv krankheitsverursachende Proteine abbauen, indem sie sich das körpereigene natürliche Proteinabbausystem zunutze machen. Das Unternehmen entwickelt das IRAK4-Programm, das sich in der klinischen Phase I zur Behandlung von immunologischen Entzündungskrankheiten wie Hidradenitis suppurativa, atopischer Dermatitis, Makrophagenaktivierungssyndrom, allgemeiner pustulöser Psoriasis und rheumatoider Arthritis befindet; IRAKIMiD-Programm zur Behandlung des MYD88-mutierten diffusen großzelligen B-Zell-Lymphoms; STAT3-Programm zur Behandlung von hämatologischen Malignomen und soliden Tumoren sowie von Autoimmunerkrankungen und Fibrose; und MDM2-Programm zur Behandlung von hämatologischen Malignomen und soliden Tumoren. Das Unternehmen wurde im Jahr 2015 gegründet und hat seinen Hauptsitz in Watertown, Massachusetts.
| Nombre | KYMERA THERAP.INC. -,0001 |
| CEO | Nello Mainolfi |
| Sede | Watertown,
ma Estados Unidos |
| Sitio web | |
| Sector | Consumo básico |
| Industria | Productos alimenticios |
| Salida a bolsa | 21/08/2020 |
| Empleados | 273 |
Deep Dive
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | KYMR |
Descubrir activos
Los accionistas de KYMERA THERAP.INC. -,0001 también invierten en los siguientes activos
